PolyPid Ltd. Announces Pricing of Initial Public Offering

Petah Tikva, Israel – June 26, 2020 – PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced the pricing of its initial public offering of